newsfilter
← Latest News
GlobeNewswire·

GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease

SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it initiated the Phase 2 portion of a planned Phase 2/3 trial of GBT021601 (GBT601), the company's investigational n